CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 76 enrolled
Drug / intervention
ATH-399A +6 moredrug
Likely dose
ATH-399A 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06088784
NCT06088784Phase 1Completed
CompareCT.gov

A Randomized, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses as Well as the Food Effect of Orally Administered ATH-399A in Healthy Adult Participants

HanAll BioPharma Co., Ltd.·interventional·Posted Oct 18, 2023·Updated Dec 19, 2025

In Brief

A Phase 1 clinical trial evaluating ATH-399A, Placebo, and 5 other interventions for Healthy Volunteers. Completed, enrolled 76 participants across 1 site.

Detailed Summary

This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or disease-modifying treatments for Parkinson Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesCanada
CollaboratorsNurrOn Pharmaceuticals, Inc.

Timeline

Phase 1CompletedFinished
202420252026
First PostedOct 18, 2023
Enrollment StartSep 19, 2023
Primary CompletionApr 24, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.7 years ago

Interventions

ATH-399Adrug

Orally administered drug in capsule form.

Placebodrug

Orally administered drug in capsule form.

ATH-399A 10 mgdrug

Participants will receive single oral dose of 10 mg of ATH-399A capsule

5 mg ATH-399A capsuledrug

Participants will receive single oral dose of 5mg of ATH-399A capsule

20mg ATH-399A capsuledrug

Participants will receive single oral dose of 20mg of ATH-399A capsule

40mg ATH-399A capsuledrug

Participants will receive single oral dose of 40mg of ATH-399A capsule

80mg ATH-399A capsuledrug

Participants will receive single oral dose of 80mg of ATH-399A capsule